Foresight Biotherapeutics Announces Positive Results from an Open Label Pilot Study in Patients with Viral Conjunctivitis


  • Complete Resolution of Viral Conjunctivitis Clinical Symptoms within 72 Hours
     
  • Reduction in Viral Titers and Elimination of Viral Infectivity
     
  • No Adverse Events
     


 

NEW YORK--(BUSINESS WIRE)--Jul 21, 2009 - Foresight Biotherapeutics, Inc. announced completion of a multi-center open-label pilot study of FST100 in the treatment of viral conjunctivitis. FST-100 is a novel formulation of dexamethasone that includes povidone iodine. The trial studied patients with clinical signs and symptoms of acute conjunctivitis who tested positive for adenoviral antigen by the RPS Adeno Detector® (RPS). Patients were enrolled in a single arm utilizing FST-100 topical ophthalmic suspension given 4 times daily for 5 days. The RPS Adeno Detector® test was performed at baseline and at each visit along with conjunctival swabs for adenoviral titers by quantitative PCR (qPCR) and cell culture with confirmatory immunoflourescence (CC-IFA). The primary endpoint of the study was clinical resolution of conjunctival injection and conjunctival discharge. These signs were scored on a scale from zero to three. Secondary endpoints included reduction of viral titers measured by qPCR and eradication of infectious virus determined by CC-IFA.


 

FST-100 met the primary endpoint of the study by demonstrating complete resolution of conjunctivitis signs (a score of zero) in all eyes completing the study. One patient was lost to follow-up. In all RPS positive eyes with confirmed viral infection by qPCR and CC-IFA clinical symptoms resolved within 72 hours. All eyes completing the study with detectable adenovirus by qPCR demonstrated significant reduction in viral titers by 48-96 hours and the majority demonstrated elimination of infectivity by CC-IFA by 72-96 hours. There were no adverse events in the study.


 

Lead investigator Jesse Pelletier, M.D. commented, “We are excited about this preliminary data and look forward to enrolling patients in a larger controlled clinical study. Currently, there are no drugs approved for the treatment of viral conjunctivitis and it is certainly an area of unmet medical need.”


 

About Foresight Biotherapeutics, Inc.


 

Foresight Biotherapeutics is a drug development company focused on diseases of the eye and ear. The company's website is: www.foresightbiotherapeutics.com.


 

Safe Harbor Statement Regarding Forward-looking Statements


 

The statements in this release and oral statements made by representatives of Foresight relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Foresight's product candidates are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Foresight and/or its partners to develop, manufacture and commercialize, Foresight's ability to fund such efforts with or without partners, and other risks.


 

 


 

 


 

Contact: For Further Information:

Foresight Biotherapeutics

Investor Relations, 646-747-9100

admin@foresightbio.com


 

 


 

 

Posted: July 2009

View comments

Hide
(web5)